The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $1.83 in the prior trading day, GlycoMimetics Inc (NASDAQ: GLYC) closed at $0.32, down -82.76%. In other words, the price has decreased by -$82.76 from its previous closing price. On the day, 40.61 million shares were traded. GLYC stock price reached its highest trading level at $0.42 during the session, while it also had its lowest trading level at $0.312.
Ratios:
Our goal is to gain a better understanding of GLYC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.41 and its Current Ratio is at 6.41. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on December 22, 2023, initiated with a Overweight rating and assigned the stock a target price of $12.
On November 12, 2021, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $3 to $4.
On November 14, 2019, ROTH Capital started tracking the stock assigning a Buy rating and target price of $12.ROTH Capital initiated its Buy rating on November 14, 2019, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 22 ’23 when Rock Edwin bought 30,403 shares for $1.38 per share. The transaction valued at 41,956 led to the insider holds 375,403 shares of the business.
Rock Edwin bought 35,000 shares of GLYC for $48,300 on Sep 21 ’23. The Chief Medical Officer now owns 345,000 shares after completing the transaction at $1.38 per share. On May 17 ’23, another insider, Hahn Brian M., who serves as the SVP Finance, CFO of the company, sold 3,700 shares for $1.95 each. As a result, the insider received 7,215 and left with 53,143 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLYC now has a Market Capitalization of 117944304 and an Enterprise Value of -20650332. For the stock, the TTM Price-to-Sale (P/S) ratio is 2033.40 while its Price-to-Book (P/B) ratio in mrq is 0.53. Its current Enterprise Value per Revenue stands at -2065.033 whereas that against EBITDA is 0.528.
Stock Price History:
Over the past 52 weeks, GLYC has reached a high of $3.53, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -87.52%, while the 200-Day Moving Average is calculated to be -84.77%.
Shares Statistics:
The stock has traded on average 518.81K shares per day over the past 3-months and 1052370 shares per day over the last 10 days, according to various share statistics. A total of 64.39M shares are outstanding, with a floating share count of 58.40M. Insiders hold about 9.39% of the company’s shares, while institutions hold 46.86% stake in the company. Shares short for GLYC as of 1713139200 were 3012763 with a Short Ratio of 5.81, compared to 1710460800 on 1490809. Therefore, it implies a Short% of Shares Outstanding of 3012763 and a Short% of Float of 6.74.
